Stay updated with breaking news from Takeda eden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase Inhibitor ....
TOKYO (dpa-AFX) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) reported that its net profit for the nine-month period ended December 31, 2022 increased by 18.4% to 285.9 billion yen from ....
BEIJING (dpa-AFX) - Takeda Pharmaceutical Co. Ltd. (TKPHF.PK, TAK) Wednesday announced that Exkivity or mobocertinib has been approved by the National Medical Products Administration of China. ....
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Takeda (TAK) announced that the totality of evidence from a pre-planned interim analysis of a Phase 3 study supports the efficacy and safety of TAK-755 as enzyme ....